| 产品描述: | VU0071063 is a potent and specific Kir6.2/SUR1 opener (EC50=7.44 μM) and can be used for investigating Kir6.2/SUR1 expressed in the pancreas and brain. VU0071063 inhibits insulin secretion by inducing hyperpolarization of β-cell membrane potential. VU0071063 chemotype has a very steep structure-activity relationships |
| 靶点: |
EC50: 7.44 μM (Kir6.2/SUR1) |
| 体内研究: |
VU0071063 (50 mg/kg; i.p.; 4 hours) leads to a significant increase in blood glucose at 60 minutes. Animal Model: Male C57BL/6 mice (10-12 weeks age) Dosage: 50 mg/kg (Pharmacokinetic analysis) Administration: I.p. Result: Led to a significant increase in blood glucose at 60 minutes. |
| 参考文献: |
1. Kharade SV, et al. Structure-Activity Relationships, Pharmacokinetics, and Pharmacodynamics of the Kir6.2/SUR1-Specific Channel Opener VU0071063. J Pharmacol Exp Ther. 2019;370(3):350-359. 2. Raphemot R, et al. Direct activation of β-cell KATP channels with a novel xanthine derivative. Mol Pharmacol. 2014;85(6):858-865. |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
3.064 ml |
15.319 ml |
30.638 ml |
| 5 mM |
0.613 ml |
3.064 ml |
6.128 ml |
| 10 mM |
0.306 ml |
1.532 ml |
3.064 ml |
| 50 mM |
0.061 ml |
0.306 ml |
0.613 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |